USPTO serial 85563050
MEDCISION
Reviewed by CopyMark Law Group
Reg. 5151370Status 710
- Filing date
- Status date
- Registration date
- Feb 28, 2017
- Examiner
- SOUDERS, MICHAEL J
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with MEDCISION?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
San Rafael, CA
San Rafael, CA
Mill Valley, CA
BOTHELL, WA
MENLO PARK, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Garth E. Coviello
Garth E. Coviello Brown and Michaels, PC118 North Tioga Street4th FloorIthaca, NY 14850Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 010 | Medical apparatus, namely, integrated and standardized systems consisting primarily of medical sample tubes, pipettes and pipette tips, sample plates for bacterial, yeast and tissue culture, glassware for reagent storage and use, electrophoresis apparatuses for medical use, separation columns, HPLC apparatus for small molecule detection, separation and isolation, centrifuges, agarose gels, growth medium, precast SDS-PAGE protein gels for small molecule detection, separation and isolation, gel cassettes and combs for use with SDS-PAGE and agarose gels, enzyme-linked immunosorbent assays, PCR and RT-PCR apparatus for amplification of DNA, DNA microarrays, freezer apparatuses for cryogenic preservation of tissue samples, cryogenic transfer and storage apparatuses, thermal management apparatuses for regulating and maintaining a desired temperature of tissue samples, cold chain logistics apparatuses for ensuring an unbroken series of storage and distribution activities which maintain a given temperature range of tissue samples, apparatuses for freezing and thawing cells, viruses, microorganisms, bacterium, tissues, vaccines, blood, blood products, and cold chain logistics, cell and stem cell therapy apparatuses for isolating, culturing, freezing, preserving and administering cell and stem cell tissues, spectrometers, and chromatography systems consisting of hydrophobic interaction chromatography, ion exchange chromatography, affinity chromatography, metal binding, and immunoaffinity chromotography for collection, stabilization, purification and analysis of proteins, cells, RNA, microRNA, DNA and biomarkers from blood, bone marrow and tissue specimens for clinical and medical diagnostic use; Preanalytical systems consisting primarily of syringes, needles, catheters, petri dishes, sample tubes, test tube rockers, vacuum sample tubes, lancets, glassware for reagent storage and use, intravenous tubing, intravenous bags, urine collection containers, pipettes and pipette tips, syringes, sample plates, electrophoresis apparatuses for medical use, separation columns, HPLC apparatuses for small molecule detection, separation and isolation, centrifuges, agarose gels, growth medium, precast SDS-PAGE protein gels for small molecule detection, separation and isolation, gel cassettes and combs for use with SDS-PAGE and agarose gels, enzyme-linked immunosorbent assays, PCR and RT-PCR apparatuses for amplification of DNA, DNA microarrays, spectrometers, and chromatography systems, namely, hydrophobic interaction chromatography, ion exchange chromatography, affinity chromatography, metal binding, and immunoaffinity chromotography for molecular medical diagnostic uses; Medical apparatus for analyzing clinically relevant biomarkers for diagnosing or treating cancer, inflammatory bowel disease, Crohn's disease, Parkinson's disease, HIV, rheumatoid arthritis, obesity, Alzheimer's disease, Huntington's disease, Celiac disease, heart function, cardiovascular disease, lung disease, cholesterol, diabetes, nutritional deficiencies, aging, and chronic kidney disease; Medical kits consisting of integrated and standardized systems consisting primarily of medical sample tubes, pipettes and pipette tips, sample plates for bacterial, yeast and tissue culture, glassware for reagent storage and use, electrophoresis apparatuses for medical use, separation columns, HPLC apparatus for small molecule detection, separation and isolation, centrifuges, agarose gels, growth medium, precast SDS-PAGE protein gels for small molecule detection, separation and isolation, gel cassettes and combs for use with SDS-PAGE and agarose gels, enzyme-linked immunosorbent assays, PCR and RT-PCR apparatus for amplification of DNA, DNA microarrays, freezer apparatuses for cryogenic preservation of tissue samples, cryogenic transfer and storage apparatuses, thermal management apparatuses for regulating and maintaining a desired temperature of tissue samples, cold chain logistics apparatuses for ensuring an unbroken series of storage and distribution activities which maintain a given temperature range of tissue samples, apparatuses for freezing and thawing cells, viruses, microorganisms, bacterium, tissues, vaccines, blood, blood products, and cold chain logistics, cell and stem cell therapy apparatuses for isolating, culturing, freezing, preserving and administering cell and stem cell tissues, spectrometers, and chromatography systems consisting of hydrophobic interaction chromatography, ion exchange chromatography, affinity chromatography, metal binding, and immunoaffinity chromotography for collection, stabilization, purification and analysis of proteins, cells, RNA, microRNA, DNA and biomarkers from blood, bone marrow and tissue specimens for clinical and medical diagnostic use; Medical devices for collection, stabilization, purification and analysis of proteins, cells, RNA, microRNA, DNA and biomarkers from blood, bone marrow and tissue specimens, and software sold as a unit therewith for clinical and medical diagnostic use | SECTION 8 - CANCELLED | Jan 16, 2017 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Biocision, LLC
- Other trademarks owned by Biocision, LLC
- Other trademarks owned by Biocision, LLC
- Other trademarks owned by BIOLIFE SOLUTIONS, INC.
- Other trademarks owned by ASTERO BIO CORPORATION
- Other trademarks in Class 010
- Similar marks named MEDCISION
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 8, 2023 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Jul 27, 2022 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Feb 28, 2022 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Oct 26, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 26, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 26, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 26, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 26, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 27, 2019 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Aug 14, 2017 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 28, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 27, 2017 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Jan 26, 2017 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Jan 24, 2017 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jan 19, 2017 | IUAF | USE AMENDMENT FILED | — |
| Jan 19, 2017 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jul 29, 2016 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 28, 2016 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Jul 20, 2016 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jul 20, 2016 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 20, 2016 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 2, 2016 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Feb 1, 2016 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jan 21, 2016 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jan 21, 2016 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 21, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Jul 20, 2015 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jul 13, 2015 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jul 13, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 3, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Feb 28, 2015 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Feb 27, 2015 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 14, 2015 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jan 14, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 23, 2014 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Jul 21, 2014 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jul 21, 2014 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jul 21, 2014 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 21, 2014 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 26, 2013 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 6, 2013 | NPUB | NOTICE OF PUBLICATION | — |
| Oct 23, 2013 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Oct 23, 2013 | ALIE | ASSIGNED TO LIE | — |
| Oct 8, 2013 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Oct 8, 2013 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 8, 2013 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 8, 2013 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 9, 2013 | CNCF | CONTINUATION OF FINAL REFUSAL MAILED | — |
| Sep 6, 2013 | CNCF | ACTION CONTINUING A FINAL - COMPLETED | — |
| Aug 15, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 14, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 14, 2013 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jul 15, 2013 | CNCF | CONTINUATION OF FINAL REFUSAL MAILED | — |
| Jul 15, 2013 | CNCF | ACTION CONTINUING A FINAL - COMPLETED | — |
| Jun 20, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 20, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 20, 2013 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Dec 20, 2012 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 20, 2012 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 19, 2012 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 18, 2012 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 18, 2012 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 18, 2012 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 15, 2012 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 15, 2012 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 14, 2012 | MPMK | NOTICE OF PSEUDO MARK MAILED | — |
| Mar 13, 2012 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 10, 2012 | NWAP | NEW APPLICATION ENTERED | — |